Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stent shows promise in Real-World heart patients

NCT ID NCT05677711

Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 204 people with coronary artery disease who received the Ultimaster stent, a thin mesh tube coated with a drug that slowly releases to prevent arteries from clogging again. The stent's coating dissolves over 3-4 months. Researchers tracked safety and effectiveness over one year, looking at heart-related deaths, heart attacks, and the need for repeat procedures. The goal was to see how well the stent works in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultimaster sirolimus-eluting coronary stent (a mesh tube coated with a drug that prevents artery re-blockage)
What this could lead to
If successful, this could confirm that the Ultimaster stent is a safe and effective option for treating blocked heart arteries in a wide range of patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The stent still carries risks like blood clots or artery re-narrowing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

204 people

The number who actually took part.

Started

Jul 2021

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients treated with Ultimaster® stents

Ages

19 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 19 or older 2. Clinical evidence of coronary artery disease, including asymptomatic ischemia, stable angina, and acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction) 3. No restrictions on the number of blood vessels, number of lesions, and length of lesions 4. Those who voluntarily gave written consent to participate in this clinical study Exclusion Criteria: 1. Life expectancy within 1 year 2. Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, prasugrel, ticagrelor 3. If other researchers judge that it is inappropriate to participate in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Drug-eluting stents

Contacts and locations

Locations

  • Yongin Severance Hospital

    Yongin, Gyeonggi-do, 16995, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.